This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Bruce Ettinger, MD
Kaiser-Permanente Medical Center San Francisco

JAMA. 1982;248(16):1971.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The appearance of deposits of triamterene in kidney stones is now widely recognized (1980; 244:2443 and 1981;245:2494).^1-4 We previously reported² that 0.4% of all kidney stones analyzed showed some deposits of this drug. We estimated the annual incidence of triamterenecontaining stones to be 1/2,000 users of a mixture of triamterene and hydrochlorothiazide (Dyazide).³

We have done an epidemiologic study to define the risk of kidney stones better in patients exposed to triamterene. We compared 799 patients attending the Kaiser-Permanente Medical Center clinics, San Francisco, who had regularly used Dyazide, with age- and sex-matched control subjects of two types. One group had used hydrochlorothiazide regularly, and the other group received no diuretic therapy. Patients with a history of kidney stones were excluded. The mean duration of follow-up was almost five years, and the mean dosage of Dyazide was one capsule a day, with 17% of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?